Compare Sanofi SA (SNY) vs TotalEnergies SE (TTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TotalEnergies SE — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while TotalEnergies SE trades at $91.36 (market cap $200.03B). The key difference: TotalEnergies SE is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.61%). Which is the better fit depends on your goals.
| SNY | TTE | |
|---|---|---|
Market Cap | $104.06B | $200.03B |
Sector | Health | Energy |
52-Week High | $52.34 | $93.60 |
52-Week Low | $41.33 | $57.39 |
Enterprise Value | $124.09B | $231.02B |
Dividend Yield | 5.61% | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
TotalEnergies (TTE) trades at $90.1, up 1.7% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $98. Recent earnings show a beat in Q2 2026, and the company is advancing key LNG projects in Papua New Guinea and Angola. Cash flow improved to a positive $358 million in 2025, though revenue has declined from 2022 peaks.
The outlook is positive given analyst support and strategic investments, but risks include volatile oil prices and execution challenges. The stock offers value with a P/E of 11.28 and a 9.08% net margin, supported by a strong dividend history. Investors should weigh growth initiatives against energy market cyclicality.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →
